830 Winter St
About ImmunoGen Inc.
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is being advanced to Phase 3 testing for FRα-positive platinum-resistant ovarian cancer, and is also in Phase 1b/2 testing in combination regimens for earlier-stage disease. The Company's ADC technology is used in three other clinical-stage ImmunoGen product candidates, in Roche's marketed product, Kadcyla®, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda.
447 articles with ImmunoGen Inc.
ImmunoGen, Inc. Announces Conference Call To Discuss Its Second Quarter Fiscal Year 2006 Financial Results
ImmunoGen, Inc. Announces Genentech, Inc. Has Taken Fourth License To Use ImmunoGen's TAP Technology To Develop Novel Anticancer Therapeutics
ImmunoGen, Inc. Announces Presentation Of HuN901-DM1; Clinical Activity Reported Includes Sustained Complete Remission And Stable Disease
ImmunoGen, Inc. Announces Webcast Of Its Presentation At The CIBC World Markets 16th Annual Healthcare Conference